Adding vistusertib to fulvestrant failed to demonstrate a benefit over everolimus in patients with ER-positive advanced or metastatic breast cancer.
Treatment with gonadotropin-releasing hormone analog can safely and effectively protect ovarian function and has the potential to preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.
In this interview, we discuss the biology and the therapeutic strategies for primary mediastinal B-cell lymphoma.
An antibody–drug conjugate known as sacituzumab govitecan demonstrated significant clinical activity in heavily pretreated patients with relapsed/refractory metastatic triple-negative breast cancer, according to a new study.
A study found no difference in outcomes between 2 and 5 years of treatment with zoledronate after chemotherapy in early breast cancer patients, suggesting the longer duration may not be necessary.
The combination of pembrolizumab and trastuzumab showed promising clinical benefit in patients with trastuzumab-resistant HER2-positive advanced breast cancer who express PD-L1, according to a new study.
The addition of the CDK4/6 inhibitor ribociclib to endocrine therapy with either tamoxifen or an aromatase inhibitor significantly improved progression-free survival among premenopausal and perimenopausal women with breast cancer.
A post-hoc analysis found that brain metastases are more frequent in patients with advanced germ cell tumors who have received dose-dense chemotherapy compared with those administered the BEP regimen.
Increasing chemotherapy dose intensity reduced the risk of recurrence and death over standard chemotherapy regimens, according to a meta-analysis of women with early-stage breast cancer.
Adding trastuzumab to adjuvant chemotherapy did not result in improved rates of invasive disease-free survival in patients with early-stage breast cancer and low levels of HER2 expression, according to a new study.
Although a longer progression-free survival is of high importance to CLL patients, a reduced risk of serious adverse events might be worth a tradeoff for some efficacy.
The FDA approved a biosimilar for trastuzumab, Ogivri, for the treatment of patients with HER2-positive breast and stomach cancer.
In this interview ahead of the ASH Annual Meeting we discuss the current management of Philadelphia chromosome–positive acute lymphoblastic leukemia and the role of stem cell transplantation.
Traditional neoadjuvant chemotherapy along with dual HER2-targeted blockade yielded significantly better response rates than a novel approach using HER2-targeted chemotherapy plus HER2-targeted blockade, according to a randomized phase III trial.
A novel classification system that incorporates genomic risk with clinical variables was able to accurately identify prostate cancer patients at low, intermediate, and high risk for metastasis.